# US 11,029,311 B2 · Method for determining a concentration of epithelial cells in a blood sample or aspirate sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,029,311 B2
- Document ID: US11029311B2
- Status: Granted
- Kind: B2
- Application number: 15/751,071
- Filed: 2016-08-03
- Published: 2018-08-16
- Granted: 2021-06-08
- Earliest claimed: 2015-08-07
- Applicants: Ulrich Fachmann; Katharina Fachmann
- Inventors: Ulrich Fachmann; Katharina Fachmann
- Web page: https://patentgrep.com/patent/US11029311B2

## CPC

- G01N 33/56966: {Animal cells}
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for determining a concentration of epithelial cells in a blood sample or aspirate sample originating from a human being or mammal and mixed with anti-clotting agent. Here, following the addition of antibodies, antibody fragments, or antibody mimetica, which are each aimed against an antigen that is specific to epithelial cells, the sample is incubated until a decreasing binding rate of the binding of the antibodies, antibody fragments, or antibody mimetica to the cells is achieved. Only then is the number of marked cells and the original concentration of the cells in the blood sample or aspirate sample determined.

## Claims

### Claim 1

A method for determining a concentration of epithelial cells in a blood sample or aspirate sample which originates from a human or mammal and has been admixed with an anticoagulant, comprising the following steps:
a) lysing the erythrocytes present in the blood sample or aspirate sample by addition of a buffer which brings about a lysis of the erythrocytes, segregating cells which are not lysed in the course of this, and suspending the segregated cells in a buffer, wherein the blood sample or the aspirate sample is stored at a temperature between 0 and 40° C. for at least 24 hours before the erythrocytes are lysed,
b) adding antibodies, antibody fragments or antibody mimetics which each bear at least one label and which are each directed against the epithelial cell adhesion molecule (EpCAM) and/or at least one other antigen specific for epithelial cells to a cell suspension obtained in step a) or to a subquantity of said cell suspension, which subquantity has been obtained by segregation, mixing the antibodies, antibody fragments or antibody mimetics and the cell suspension or the subquantity, and incubating a mixture obtained as a result for at least a time which is required for the attainment of a decreasing binding rate of binding of the antibodies, antibody fragments or antibody mimetics to the cells, wherein the incubation is done for at least 12 hours,
c) determining the number of cells labeled by binding of the antibodies, antibody fragments or antibody mimetics, in the mixture obtained in step b), and
d) calculating the concentration of the labeled cells, the number of which has been determined in step c), in the blood sample or aspirate sample.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the following further steps are carried out between steps a) and b):
a1) segregating at least one subquantity or a further subquantity of the cell suspension obtained in step a),
a2) adding the antibodies, antibody fragments or antibody mimetics which each bear at least one label and which are each directed against the epithelial cell adhesion molecule (EpCAM) and/or at least one other antigen specific for epithelial cells to the further subquantity in such a quantity that the concentration thereof in the further subquantity is identical to the concentration of the antibodies, antibody fragments or antibody mimetics in the cell suspension or the subquantity according to step b), mixing the antibodies, antibody fragments or antibody mimetics and the further subquantity, and incubating a mixture obtained as a result at a predefined temperature and
a3) continuously or repeatedly determining a quantity of said antibodies, said antibody fragments or said antibody mimetics which have bound to cells present in the further subquantity as a function of time starting from the mixing according to step a2), ascertaining a binding rate therefrom, and determining a time which is required for the attainment of a decreasing binding rate of the binding of said antibodies, said antibody fragments or said antibody mimetics to said cells,
wherein the incubation in step b) is done at the predefined temperature, wherein the time according to step b) is selected such that it is at least as long as the time determined in step a3).

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein the incubation according to step b) is done at a predefined temperature and/or wherein the predefined temperature is a temperature in the range from 0 to 30° C.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein the incubation according to step b) is done for at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours, at least 24 hours, at least 25 hours, at least 26 hours, at least 27 hours, at least 28 hours, at least 29 hours, or at least 30 hours.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein the label is a fluorescent label by means of a fluorochrome, a color label by means of a chromophore, or an indirectly detectable label by means of an affinity tag, epitope tag or protein tag.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein the determination of the number of cells labeled by binding of the antibodies, antibody fragments or antibody mimetics according to step c) is done by means of laser scanning cytometry, fluorescence microscopy or light microscopy.

### Claim 7 (depends on 6)

The method as claimed in claim 6, wherein the determination of the quantity of bound antibodies, antibody fragments or antibody mimetics and/or the determination of the number of labeled cells is done by means of fluorescence microscopy or light microscopy and an image recognition software is used to identify the cells.

### Claim 8 (depends on 6)

The method as claimed in claim 6, wherein the label is a fluorescent label and wherein determined, at different times, in the laser scanning cytometry or the fluorescence microscopy for each of the cells are a total fluorescence per cell and a background fluorescence for said cell, such that equivalent fluorescence values are obtained for the cells, in each case as the difference between the total fluorescence ascertained for the particular cell and the background fluorescence ascertained for said cell.

### Claim 9 (depends on 1)

The method as claimed in claim 1, wherein the segregation according to step a) is done by centrifugation, sedimentation or filtration.

### Claim 10 (depends on 1)

The method as claimed in claim 1, wherein a blocking reagent for the blocking of nonspecific binding sites and/or of Fc receptors is added to the cell suspension or the subquantity of the cell suspension and mixed and incubated with the cell suspension or the subquantity of the cell suspension, in each case before the addition of antibodies, antibody fragments or antibody mimetics which each bear at least one label according to steps b).

### Claim 11 (depends on 1)

The method as claimed in claim 1, wherein in none of the steps is a detergent used and/or in none of the steps are the cells fixed.

### Claim 12 (depends on 1)

The method as claimed in claim 1, wherein all the steps of the method or at least steps b) and c) are carried out automatically by a machine.

### Claim 13 (depends on 2)

The method as claimed in claim 2, wherein two or more subquantities are segregated in step a1), wherein, in step a2), a different quantity of the antibodies, antibody fragments or antibody mimetics is added in each case to each of the subquantities and mixed with the respective subquantity, wherein, in step a3), the time required for the attainment of the decreasing binding rate is determined for each of the subquantities, wherein that quantity of the antibodies, antibody fragments or antibody mimetics in which the decreasing binding rate is attained within a desired time is then selected for the performance of step b).

### Claim 14 (depends on 1)

The method as claimed in claim 1, wherein the other antigen specific for epithelial cells is selected from the group consisting of: androgen receptor, epithelial growth factor receptor (EGF receptor), estrogen receptor, progesterone receptor, prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), programmed death ligand 1 (PDL-1), melan A, B7-H3, vascular endothelial growth factor receptor (VEGF receptor), Ki67, insulin-like growth factor receptor (IGF receptor) and Her2neu.

### Claim 15 (depends on 7)

The method as claimed in claim 7, wherein the label is a fluorescent label and wherein determined, at different times, in the laser scanning cytometry or the fluorescence microscopy for each of the cells are a total fluorescence per cell and a background fluorescence for said cell, such that equivalent fluorescence values are obtained for the cells, in each case as the difference between the total fluorescence ascertained for the particular cell and the background fluorescence ascertained for said cell.

### Claim 16 (depends on 5)

The method as claimed in claim 5, wherein the indirectly detectable label is by means of biotin, avidin, or streptavidin.

### Claim 17 (depends on 2)

The method as claimed in claim 2, wherein the determination of the quantity of bound antibodies, antibody fragments or antibody mimetics according to step a3) is done by means of laser scanning cytometry, fluorescence microscopy or light microscopy.

### Claim 18 (depends on 2)

The method as claimed in claim 2, wherein a blocking reagent for the blocking of nonspecific binding sites and/or of Fc receptors is added to the cell suspension, the subquantity or the further subquantity of the cell suspension and mixed and incubated with the cell suspension, the subquantity or the further subquantity of the cell suspension, in each case before the addition of antibodies, antibody fragments or antibody mimetics which each bear at least one label according to steps b) and a2).

### Claim 19 (depends on 2)

The method as claimed in claim 2, wherein all the steps of the method or at least steps b), a2), a3) and c) are carried out automatically by a machine.